Alexandra Balcom Sells 4,236 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) CFO Alexandra Balcom sold 4,236 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $97.32, for a total transaction of $412,247.52. Following the completion of the sale, the chief financial officer directly owned 84,914 shares in the company, valued at $8,263,830.48. This represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Alexandra Balcom also recently made the following trade(s):

• On Tuesday, January 6th, Alexandra Balcom sold 3,181 shares of Nuvalent stock. The stock was sold at an average price of $97.16, for a total transaction of $309,065.96.
• On Monday, December 8th, Alexandra Balcom sold 7,084 shares of Nuvalent stock. The shares were sold at an average price of $110.32, for a total transaction of $781,506.88.
• On Monday, November 17th, Alexandra Balcom sold 20,000 shares of Nuvalent stock. The stock was sold at an average price of $99.45, for a total transaction of $1,989,000.00.
• On Tuesday, November 18th, Alexandra Balcom sold 729 shares of Nuvalent stock. The stock was sold at an average price of $104.26, for a total value of $76,005.54.
• On Wednesday, October 15th, Alexandra Balcom sold 1,683 shares of Nuvalent stock. The shares were sold at an average price of $85.57, for a total value of $144,014.31.
• On Monday, October 13th, Alexandra Balcom sold 20,000 shares of Nuvalent stock. The shares were sold at an average price of $88.51, for a total value of $1,770,200.00.

Nuvalent Trading Down 3.9%

Shares of NUVL opened at $102.67 on Friday. Nuvalent, Inc. has a 52 week low of $55.53 and a 52 week high of $112.88. The firm has a market cap of $7.47 billion, a price-to-earnings ratio of -19.30 and a beta of 1.32. The stock has a 50 day moving average of $102.73 and a 200-day moving average of $89.01.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same period in the previous year, the company posted ($1.28) earnings per share. On average, sell-side analysts predict that Nuvalent, Inc. will post -3.86 earnings per share for the current fiscal year.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: Analysts remain constructive — several firms have recently initiated/raised coverage and price targets (Cantor Fitzgerald, Leerink, Baird, Goldman Sachs, Truist among others), leaving a consensus target near $138 that supports longer-term upside. MarketBeat Nuvalent Coverage
• Neutral Sentiment: Company fundamentals reminder — Nuvalent is clinical-stage (lead assets NVL‑520, NVL‑655) and reported an EPS miss on Oct. 30 (($1.70) vs. ($1.39) expected); pipeline readouts and clinical data remain the key medium-term catalysts/risks. Earnings / Profile
• Neutral Sentiment: Institutional ownership is very high (~97%), and some small funds added modest positions recently — this reduces free-float liquidity but can amplify moves when insiders trade. Institutional Activity
• Negative Sentiment: Concentrated insider selling: CEO James R. Porter sold large blocks (17,890 shares on Jan. 5 and 9,543 shares on Jan. 6 at ~ $97 / share), a material reduction in his position that likely weighs on sentiment. SEC Filing – CEO Sales
• Negative Sentiment: CFO Alexandra Balcom and other insiders (director Christopher D. Turner, Deborah A. Miller, Henry E. Pelish) also sold multiple tranches on Jan. 5–6 (several thousand shares each), collectively trimming insider stakes and adding selling pressure. SEC Filing – CFO Sales SEC Filing – Turner SEC Filing – Miller SEC Filing – Pelish

Institutional Trading of Nuvalent

A number of hedge funds have recently made changes to their positions in NUVL. Voya Investment Management LLC raised its position in Nuvalent by 6.6% during the first quarter. Voya Investment Management LLC now owns 120,311 shares of the company’s stock valued at $8,532,000 after acquiring an additional 7,414 shares in the last quarter. Rhumbline Advisers grew its position in Nuvalent by 24.5% in the second quarter. Rhumbline Advisers now owns 66,029 shares of the company’s stock worth $5,038,000 after acquiring an additional 13,003 shares in the last quarter. Voleon Capital Management LP acquired a new position in shares of Nuvalent during the 1st quarter worth $1,489,000. Norges Bank bought a new position in shares of Nuvalent during the 2nd quarter valued at $28,582,000. Finally, Strs Ohio bought a new position in shares of Nuvalent during the 1st quarter valued at $404,000. 97.26% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the company. HC Wainwright lifted their target price on Nuvalent from $130.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a report on Wednesday, October 8th. Cantor Fitzgerald initiated coverage on Nuvalent in a research report on Wednesday, October 15th. They set an “overweight” rating and a $135.00 price objective for the company. Leerink Partners upped their price objective on Nuvalent from $140.00 to $149.00 and gave the stock an “outperform” rating in a research note on Monday, November 17th. Finally, UBS Group reaffirmed a “buy” rating on shares of Nuvalent in a research report on Wednesday, December 17th. Fifteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nuvalent currently has a consensus rating of “Moderate Buy” and an average price target of $138.33.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.